#### The PTEN Study: Eligibility Criteria and Clinical Features Checklist

Please note that patient results will not be released until all required study documents and confirmatory records have been received.

If this information is not available to you for inclusion with the patient's sample and other required paperwork, please ensure that the institution(s) where these records may be found is listed on the medical release form so our research team can retrieve this information.

Also please note: whether macrocephaly is present or not, an OFC measurement is now a requirement for study participation. Our study will allow the following measurements to "count" as macrocephaly for adults:

Men: Minimum of 58.0 cm
Women: Minimum of 57.3 cm

### Eligibility Criteria

Patients with the following will automatically qualify for study participation:

- Known PTEN mutation or variant of uncertain significance
- Lhermitte-Duclos disease
- Pigmented macules of the glans penis
- Clinical diagnosis of Proteus or Proteus-like syndrome
- Adult patients with a score of 10 or greater per the Cleveland Clinic PTEN Risk Calculator (website: http://www.lerner.ccf.org/gmi/ccscore/)
- Pediatric patients with macrocephaly plus at least one of the following:
  - o Autism/mental retardation/developmental delay
  - o Lipoma, biopsy-proven trichilemmoma, oral papillomatosis, or hemangioma
  - o Arteriovenous malformation
  - o One or more gastrointestinal polyp(s)

In addition, patients with the following combination of findings from our clinical features checklist will qualify for study participation:

- Two major criteria
- One major plus two minor criteria
- Three minor criteria

#### **Exclusion Criteria**

#### Please do not submit the following:

- Patients with genetic tests (i.e. BRCA testing) pending
- Patients with other diagnostic testing that explains their major features (example: patient has endometrial cancer, fibrocystic breast disease, and lipoma but also has deleterious MSH2 mutation)
- Patients for whom pathology records are unattainable or at an unknown institution.

If you have a question about whether or not your patient qualifies for this study, please send a clinical summary and a copy of the pedigree to the study team for review by fax: (216) 636-0009 or email: pten@ccf.org.

CCF IRB #: IRB 8458 Approval Date: 9/23/2025 Expiration Date: 9/22/2026

The Cleveland Clinic

IRB 8458: Molecular Mechanisms Involved in Cancer Predisposition

#### Subject Consent to Contact Form

I have reviewed the information provided about the research study and I am interested in learning more. A representative from The Genomic Medicine Institute has permission to contact me regarding study participation. Phone number: (\_\_\_\_\_\_\_ Preferred days/times: \_\_\_\_\_\_ Alternate number: (\_\_\_\_\_\_\_ Preferred days/times: \_\_\_\_\_\_ Today's date: \_\_\_\_ Your signature: Print your name: If you are consenting on behalf of a child (under 18 years old), please print the child's Participant's date of birth: Contact information for health care provider facilitating study participation: Title: E-mail: \_\_\_\_\_ Phone number: (\_\_\_\_) \_\_\_\_ Please mail this form to: The Cleveland Clinic Genomic Medicine Institute 9500 Euclid Avenue, R4 Cleveland, OH 44195 OR

\_\_\_\_

FAX to:

FAX #: (216) 636-0009 Attn: Beth Crouser, MBA



### **AUTHORIZATION TO DISCLOSE HEALTH INFORMATION TO CLEVELAND CLINIC**

1. Patient Information						
Name (First, Middle, Last)		CI	Cleveland Clinic Medical Record # if known:			
Current Address		City	State		Zip	
CHICATELEMAN		- Wilky	otate			
Last 4 Digits of Social Security #	Email		Phone Numb	er I	Date of Birth	
2. Release Information From						
Facility/Provider:						
Address	City/S		Zip	Phone Number		
9500 Euclid Avenue	Cleveland, OH	44195		( )		
3. Release Information To: CLEVELA						
Name of Recipient: Facility and/or Ma	Beth Crouse	er; Genomic	Medicine Ins	titute/R4		
Address	City/S		Zip	Phone Number	Fax Number	
9500 Euclid Avenue		eland, OH	44195	(216) 445-5850	( 216) 636-0009	
	tronic delivery (If secure o					
Purpose of Disclosure:	☐ Continuity of Care		ther (please indicat	Research Participatin		
(Purpose for disclosure must be	completed prior to proces	ssing)				
Dates of service to release (FRC	)M)	(TO):				
Office Visits	History & Physic	al	F71 Hathel	ogy and Imaging Reports		
Emergency Department Reports	Other Chart Summi		X Tumor	Blocks/Slides		
III Discharge Summary	Consult Notes  Laboratory Reports		tion -	c Test Results Tree/Pedigree		
Operative Reports	Educatory (tuporus		La	Troop deligion		
I, the undersigned, authorize the above	named sending Facility/Pi	rovider as describe	d in Section 2 to rel	ease health inforn	nation as	
indicated/described above. I understand	-					
and mental illness, HIV test results or di						
does not include permission to release						
separate authorization.	омерини тороно на се	,		,		
This authorization and consent will exp	alro one year from the dat	e of authorization	written helow unl	ess revoked by me	or my legal	
representative) through written notice	_					
information that has already been relea	•		istano mat meame	nt, payment, emo	illinent, or enginity	
for benefits will not be based on whether	er or not i sign this author	ization.				
After my health information is released,	, my information may be r	e-disclosed by the	recipient and may r	o longer be prote	cted by law. I	
understand that the sender of my health	•					
inquiring about these potential charges.			•			
If Authorization is not complete, signed		urned and result i	n my information n	ot being released	until completed.	
	,				1 1	
Signature of Patient/Patient's Personal Repr	esentative	Printed N	ame		Date Signed	
Relationship, if not Patient						
*Psychotherapy Notes are defined as notes t	hat document private, joint,	group, or family cour	nseling sessions that a	re separated from ti	he rest of a patient's	

medical records.

Submit completed request to the Cleveland Clinic Facility/Mailcode identified in Section 3 above.

NOTICE: If you send health Information to Cleveland Clinic via email, please know that your message may be sent in an unencrypted email. An unencrypted email means there is a risk that the information in the email and any attachments could potentially be read by a third party when it is sent through the internet.

Revision: 10/2019

Bankir	ng Checklist: To be completed for	all studies				
	et Name:					
Date of	Date of blood draw: If CCF patient: CCF#					
Has an	nother family member enrolled into a	ny of our studies? (please circle one) Yes No				
-If so,	what is the family member's first an	d last name:				
-What	is this patient's relationship to the al					
MANDA		☐ Male ☐ Female				
Subject Race (check all that apply):						
_	☐ Asian ☐ Black or African American					
	ve Hawaiian and Other Pacific Islan					
		ic or Latino				
	ry/countries of origin:					
Enrolli	ing Healthcare Provider:	Abir in Midwelmin confidential a mail				
Please	note: patient results will be sent to	o this individual via confidential e-mail.				
Title:	Instituti	ion:				
Phone:	E-mail:					
•	Check off each required documen	nt to signify that it is included				
	-	es for which you are submitting a patient				
Requir	red from non-IRB approved	Required from IRB-approved outside sites:				
and the second s	e sites (most sites):	☐ Copy of signed informed consent form				
	ject consent to contact form	☐ Contact information page				
☐ Authorization for release of medical		☐ Authorization for release of medical information				
information		Pedigree				
☐ Pedigree		Copy of available records per study				
☐ Copy of available records per study		☐ Informed consent process documentation form/				
<b>DO NOT</b> send patient's sample with these documents.		other forms required by enrolling site's IRB				
these de	ocuments.	☐ Patient sample in provided collection kit				
	he PTEN Study					
	Meets study criteria per checklist	1.6				
Participant does not fully meet study criteria, but pre-approval for participation has						
	been obtained from genetic counselor study coordinator					
☐ Family member of previous study participant  Additional required documents:						
	☐ Completed PTEN Clinical Features Checklist					
☐ Completed SDH Clinical Features Checklist						
-	The state of the s					
	Clinic Note	CE nations submission for this study was nea-				
	General Cancer Banking: If not a CCF patient, submission for this study was preapproved by the following research team member:					
2390						
	Diagnosis:					
	□ Clinic Note					
	Completed Questionnaires					

## The PTEN Study: Clinical Features Checklist, page 1 of 2

Patient Name:	DOB;	Gender:
Patient Height:	Patient Weight:	Patient OFC (in cm):

AQ = automatic qualification; M = major criteria; m = minor criteria; see revised eligibility criteria on above page to ensure your patient qualifies.

/If * present	CNS Features	AQ/M/m	Documentation requested
	Lhermitte-Duclos disease	AQ	MRI and/or biopsy
	Macrocephaly	M	Clinic note
	Autism	m	Clinic note
	Mental retardation	m	Clinic note
	Developmental delay	m	Clinic note
If present	Endocrine Features	AQ/M/m	Documentation requested
	Thyroid cancer (not medullary)	M	Pathology report
	Goiter	m	Imaging
	Thyroid nodule(s)	m	Imaging
If present	Breast Features	AQ/M/m	Documentation requested
***************************************	Invasive carcinoma	M	Pathology report
	Ductal carcinoma in situ	m	Pathology report
	Lobular carcinoma in situ	m	Pathology report
	Breast papilloma	m	Pathology report
	Breast fibroadenoma	m	Pathology report
	Fibrocystic breast disease	m	Pathology report, imaging, and/or clinic note
√ if present	Dermatologic Features	AQ/M/m	Documentation requested
	Pigmented macules of the glans penis	AQ	Clinic note
	Biopsy-proven trichilemmoma(s)	M	Pathology report
	Oral-mucosal papillomatosis	M	Clinic note
	Lipoma(s)	m	Pathology report
√ if present	Cardiovascular Features	AQ/M/m	Documentation requested
	Arteriovenous malformation	m	Pathology report and/or imaging
I is present	Gastrointestinal Features	AQ/M/m	Documentation requested
	Hamartomatous (juvenile, Peutz- Jegher) polyp(s)	M	Pathology report
	Ganglioneuroma(s)	M	Pathology report
	Hyperplastic polyp(s)	m	Pathology report
	Glycogenic acanthosis	m	Endoscopy report
/ if present	Genitourinary Features	AQ/M/m	Documentation requested
V sapoumus	Endometrial (uterine) cancer	M	Pathology report
	Uterine fibroid(s)	m	Pathology report and/or imaging
	Renal cell (kidney) cancer	m	Pathology report
	Congenital genitourinary defect	m	Imaging or clinic note
	Other genitourinary tumor (specify):	m	Pathology and/or imaging
/ If present	Other Features	AQ/M/m	Documentation requested
	Clinical diagnosis of Proteus or Proteus-like syndrome	AQ	Clinic note

#### The PTEN Study: Clinical Features Checklist, page 2 of 2 Patient Name: DOB: Gender: Other Findings: Please circle present (P), absent (A), or unknown (U) for each. MRI-proven megencephaly P U Dermatofibroma A U A Malignant CNS tumor P A U Fibroma of other organ P U A P Benign CNS tumor U GI polyp other than listed previously A P Α U Demyelinating leukodystrophy P U Colon cancer P U A P Hemangioma of skin A U Other GI malignancy P Ū Α Hemangioma of other organ P A U Melanoma P U Α Acral keratoses P U Other malignant skin cancer P Α Α U "Skin tags", pathology unknown P U P U A Hearing loss Α Hashimoto's (chronic lymphocytic) P U Other invasive cancer(s) P A thyroiditis Specify: Other History: Please circle yes (Y) or no (N) to indicate whether or not the patient has undergone the following: Brain CT N Breast mammogram N Brain MRI Y N Breast ultrasound N Brain biopsy Y N Breast MRI Y N Thyroid ultrasound Y N Breast biopsy Y N Other thyroid scan: Y N Breast lumpectomy Y N Thyroid FNA Y N Unilateral mastectomy N Partial thyroidectomy Y N Bilateral mastectomy N Total thyroidectomy N Hysterectomy Y N Abdominal ultrasound Y N Unilateral cophorectomy Y N Abdominal CT Y N Bilateral oophorectomy N Abdominal MRI Y N CT Angiography (specify organ): Pelvic ultrasound Ÿ N Pelvic CT Y N MR Angiography (specify organ): Y N Pelvic MRI Y N Biopsy of other organ(s): Colonoscopy Y Y N N EGD/Upper endoscopy Y N Partial colectomy Y Other scans or procedures not listed here: N Y Total colectomy Y N Biopsy of any skin lesion N Other Testing: Please check to indicate whether or not the patient has had any of the following genetic tests and give results. Please include a copy of the lab report for any tests that have been done. Test name Result BRCA1/2 sequencing and 5-site rearrangement panel ☐ Positive ☐ Negative □ VUS BRCA1/2 Multisite-3 panel ☐ Positive ☐ Negative BART ☐ Negative □ VUS ☐ Positive Chromosome analysis (Karyotype or array) ☐ Abnormal ☐ Normal ☐ VUS Clinical PTEN sequencing ☐ Positive ☐ Negative □ VUS Clinical PTEN MLPA ☐ Positive ☐ Negative □ VUS Clinical PTEN promoter analysis □ VUS ☐ Negative ☐ Positive □ VUS Fragile X testing ☐ Positive ☐ Negative MSI testing ☐ High ☐ Stable ☐ Low

☐ Positive

☐ Positive

☐ Positive

☐ Negative

☐ Negative

□ Negative

IHC analysis

Other gene testing (specify):

Other gene testing (specify):

☐ Equivocal

□ VUS

□ VUS

# **CLEVELAND CLINIC FOUNDATION --- MEDICAL GENETICS FAMILY HISTORY**

Name:		CCF#:	DOB:	DOV:	
Goiter, nodules, Hashimoto     Trichilemmoma, acral keratosis, skin tags, lipor lipoma	_GC:		Esophagu Seizures Congenita Other Dx r	□ Benign breast Dz (I □ Uterine fibroid □ TAH □ BSO □ Skin ♣ □ Penile macules □ Denile macules □ AVM/hemangioma □ Lhermitte-Duclos D	Y N  □ □ Macrocephaly □ □ Autism/MR/DD □ □ Psychlatric d/o □ □ Thyroid *

oma, penile macules, oral-mucosal papillomas,